Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Mild Cognitive Impairment pipeline market report provides a comprehensive overview of the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects.
Mild Cognitive Impairment Pipeline Drugs Market by Key Targets
In the Mild Cognitive Impairment pipeline drugs market, the key targets are Amyloid Beta A4 Protein, Beta 2 Adrenergic Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glucagon Like Peptide 1 Receptor, Microtubule Associated Protein Tau, Acetylcholinesterase, Bcr-Abl Tyrosine Kinase, and Brain Derived Neurotrophic Factor.
Key Targets in the Mild Cognitive Impairment Pipeline Drugs Market
For more target insights, download a free report sample
Key MoA in the Mild Cognitive Impairment Pipeline Drugs Market
Some of the key mechanisms of action in the Mild Cognitive Impairment pipeline drugs market are Amyloid Beta A4 Protein Inhibitor, Beta 2 Adrenergic Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Agonist, Beta 2 Adrenergic Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Glucagon Like Peptide 1 Receptor Agonist, Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, and Bcr-Abl Tyrosine Kinase Inhibitor.
Mild Cognitive Impairment Pipeline Drugs Market Analysis, by MoA
To get more insights on key MoA, download a free sample report
Mild Cognitive Impairment Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Mild Cognitive Impairment pipeline drug market are oral, intravenous, subcutaneous, inhalational, nasal, buccal, intraarticular, and sublingual. Oral has the maximum number of pipeline products.
Mild Cognitive Impairment Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Mild Cognitive Impairment Pipeline Drugs Market
The key molecule types in the Mild Cognitive Impairment pipeline drugs market are Small Molecule, Monoclonal Antibody, Synthetic Peptide, Peptide, Antibody, Cell Therapy, Gene Therapy, Recombinant Protein, And Subunit Vaccine. Small molecule has the maximum number of pipeline products.
Mild Cognitive Impairment Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Mild Cognitive Impairment Pipeline Drugs Market
Some of the major companies in the Mild Cognitive Impairment pipeline drugs market are CuraSen Therapeutics Inc, AgeneBio Inc, Merck & Co Inc, Actinogen Medical Ltd, Acumen Pharmaceuticals Inc, Addex Therapeutics Ltd, Aptinyx Inc, Araclon Biotech SL, AstraZeneca Plc, and Biomed Industries Inc.
Mild Cognitive Impairment Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Mild Cognitive Impairment Pipeline Drugs Market Overview
Key Targets | Amyloid Beta A4 Protein, Beta 2 Adrenergic Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glucagon Like Peptide 1 Receptor, Microtubule Associated Protein Tau, Acetylcholinesterase, Bcr-Abl Tyrosine Kinase, and Brain Derived Neurotrophic Factor |
Key Mechanisms of Action | Amyloid Beta A4 Protein Inhibitor, Beta 2 Adrenergic Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Agonist, Beta 2 Adrenergic Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Glucagon Like Peptide 1 Receptor Agonist, Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, and Bcr-Abl Tyrosine Kinase Inhibitor |
Key Routes of Administration | Oral, Intravenous, Subcutaneous, Inhalational, Nasal, Buccal, Intraarticular, and Sublingual |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Synthetic Peptide, Peptide, Antibody, Cell Therapy, Gene Therapy, Recombinant Protein, and Subunit Vaccine |
Major Companies | CuraSen Therapeutics Inc, AgeneBio Inc, Merck & Co Inc, Actinogen Medical Ltd, Acumen Pharmaceuticals Inc, Addex Therapeutics Ltd, Aptinyx Inc, Araclon Biotech SL, AstraZeneca Plc, and Biomed Industries Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment
- The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Mild Cognitive Impairment therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Mild Cognitive Impairment therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Mild Cognitive Impairment
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Acumen Pharmaceuticals Inc
Addex Therapeutics Ltd
AgeneBio Inc
Aptinyx Inc
Araclon Biotech SL
AstraZeneca Plc
Biomed Industries Inc
CereSpir Inc
CuraSen Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
FUJIFILM Toyama Chemical Co Ltd
Gray Matter
Grespo AB
ImmunoChem Therapeutics LLC
IntelGenx Corp
INVENT Pharmaceuticals Inc
Jupiter Neurosciences Inc
KeifeRx LLC
Merck & Co Inc
NeurAegis Inc
Neuraly Inc
NKGen Biotech Inc
NLS Pharmaceutics AG
Novartis AG
Novo Nordisk AS
Octapharma AG
Partner Therapeutics Inc
Pfizer Inc
ProNeurogen Inc
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
SciSparc Ltd
Shackelford Pharma Inc
TauRx Therapeutics Ltd
UCB SA
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Mild Cognitive Impairment pipeline drug market?
In the Mild Cognitive Impairment pipeline drugs market the key targets are Amyloid Beta A4 Protein, Beta 2 Adrenergic Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glucagon Like Peptide 1 Receptor, Microtubule Associated Protein Tau, Acetylcholinesterase, Bcr-Abl Tyrosine Kinase, and Brain Derived Neurotrophic Factor.
-
What are the key mechanisms of action in the Mild Cognitive Impairment pipeline drugs market?
In the Mild Cognitive Impairment pipeline drugs market the key mechanisms of action are Amyloid Beta A4 Protein Inhibitor, Beta 2 Adrenergic Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Agonist, Beta 2 Adrenergic Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Glucagon Like Peptide 1 Receptor Agonist, Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, and Bcr-Abl Tyrosine Kinase Inhibitor.
-
What are the key routes of administration in the Mild Cognitive Impairment pipeline drugs market?
The key routes of administration in the Mild Cognitive Impairment pipeline drug market are Oral, Intravenous, Subcutaneous, Inhalational, Nasal, Buccal, Intraarticular, and Sublingual. Subcutaneous has the maximum number of pipeline products.
-
What are the key molecule types in the Mild Cognitive Impairment pipeline drugs market?
The key molecule types in the Mild Cognitive Impairment pipeline drug market are Small Molecule, Monoclonal Antibody, Synthetic Peptide, Peptide, Antibody, Cell Therapy, Gene Therapy, Recombinant Protein, and Subunit Vaccine.
-
What are the major companies in the Mild Cognitive Impairment pipeline drugs market?
In the Mild Cognitive Impairment pipeline drugs market the major companies are CuraSen Therapeutics Inc, AgeneBio Inc, Merck & Co Inc, Actinogen Medical Ltd, Acumen Pharmaceuticals Inc, Addex Therapeutics Ltd, Aptinyx Inc, Araclon Biotech SL, AstraZeneca Plc, and Biomed Industries Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.